Studies of the biogenic amine transporters. 1. Dopamine reuptake blockers inhibit [3H]mazindol binding to the dopamine transporter by a competitive mechanism: Preliminary evidence for different binding domains

1994 ◽  
Vol 19 (2) ◽  
pp. 201-208 ◽  
Author(s):  
Christina M. Dersch ◽  
Hyacinth C. Akunne ◽  
John S. Partilla ◽  
George U. Char ◽  
Brian R. de Costa ◽  
...  
2015 ◽  
Vol 353 (3) ◽  
pp. 529-538 ◽  
Author(s):  
Richard B. Rothman ◽  
Subramaniam Ananthan ◽  
John S. Partilla ◽  
Surendra K. Saini ◽  
Omar Moukha-Chafiq ◽  
...  

Synapse ◽  
2002 ◽  
Vol 43 (4) ◽  
pp. 268-274 ◽  
Author(s):  
Richard B. Rothman ◽  
Christina M. Dersch ◽  
F. Ivy Carroll ◽  
Subramaniam Ananthan

Synapse ◽  
2002 ◽  
Vol 44 (2) ◽  
pp. 94-105 ◽  
Author(s):  
Richard B. Rothman ◽  
F. Ivy Carroll ◽  
Marisela Morales ◽  
Daniel L. Rowley ◽  
Kenner C. Rice ◽  
...  

2018 ◽  
Author(s):  
Vikas Navratna ◽  
Dilip K. Tosh ◽  
Kenneth A. Jacobson ◽  
Eric Gouaux

AbstractThe human dopamine transporter(hDAT) plays a major role in dopamine homeostasis and regulation of neurotransmission by clearing dopamine from the extracellular space using secondary active transport. Dopamine is an essential monoamine chemical messenger that regulates reward seeking behavior, motor control, hormonal release, and emotional response in humans. Psychostimulants such as cocaine primarily target the central binding site of hDAT and lock the transporter in an outward-facing conformation, thereby inhibiting dopamine reuptake. The inhibition of dopamine reuptake leads to accumulation of dopamine in the synapse causing heightened signaling. In addition, hDAT is implicated in various neurological disorders and disease-associated neurodegeneration. Despite its significance, the molecular architecture of hDAT and its various conformational states are poorly understood. Instability of hDAT in detergent micelles has been a limiting factor in its successful biochemical, biophysical, and structural characterization. To overcome this hurdle, first we identified ligands that stabilize hDAT in detergent micelles. Then, we screened ∼200 single residue mutants of hDAT using high-throughput scintillation proximity assay, and identified a thermostable variant(I248Y). Here we report a robust strategy to overexpress and successfully purify a thermostable variant of hDAT in an inhibitor and allosteric ligand bound conformation.


2018 ◽  
Vol 75 (23) ◽  
pp. 4357-4370 ◽  
Author(s):  
Abla Benleulmi-Chaachoua ◽  
Alan Hegron ◽  
Marine Le Boulch ◽  
Angeliki Karamitri ◽  
Marta Wierzbicka ◽  
...  

2000 ◽  
Vol 20 (20) ◽  
pp. 7571-7578 ◽  
Author(s):  
Andrea L. Bauman ◽  
Subbu Apparsundaram ◽  
Sammanda Ramamoorthy ◽  
Brian E. Wadzinski ◽  
Roxanne A. Vaughan ◽  
...  

2019 ◽  
Vol 5 (1) ◽  
Author(s):  
Hirotaka Sekiguchi ◽  
Geoff Pavey ◽  
Brian Dean

AbstractThe dopamine hypothesis proposes that there is a hypodopaminergic state in the prefrontal cortex and a hyperdopaminergic state in the striatum of patients with schizophrenia. Evidence suggests the hyperdopaminergic state in the striatum is due to synaptic dopamine elevation, particularly in the dorsal striatum. However, the molecular mechanisms causing disrupted dopaminergic function in schizophrenia remains unclear. We postulated that the dopamine transporter (DAT), which regulates intra-synaptic dopamine concentrations by transporting dopamine from the synaptic cleft into the pre-synaptic neuron, could be involved in dopaminergic dysfunction in schizophrenia. Therefore, we measured levels of DAT in the cortex and striatum from patients with schizophrenia and controls using postmortem human brain tissue. Levels of desmethylimipramine-insensitive mazindol-sensitive [3H]mazindol binding to DAT were measured using in situ radioligand binding and autoradiography in gray matter from Brodmann’s area (BA) 10, BA 17, the dorsal striatum, and nucleus accumbens from 15 patients with schizophrenia and 15 controls. Levels of desmethylimipramine-insensitive mazindol-sensitive [3H]mazindol binding were significantly higher in BA 10 from patients with schizophrenia (p = 0.004) and significantly lower in the dorsal striatum (dorsal putamen p = 0.005; dorsal caudate p = 0.007) from those with the disorder. There were no differences in levels of desmethylimipramine-insensitive [3H]mazindol binding in BA 17 or nucleus accumbens. These data raise the possibility that high levels of DAT in BA 10 could be contributing to lower synaptic cortical dopamine, whereas lower levels of DAT could be contributing to a hyperdopaminergic state in the dorsal striatum.


Sign in / Sign up

Export Citation Format

Share Document